RomagnoniM., BeccariM., FaioloS.Abdominal pain with infusion of the peritoneal dialysis solutions relieved by alkalinization.Perit Dial Bull1984; 4: 188–9.
2.
BunchmanT.E., BanalS.H.Treatment of inflow pain by pH adjustment of dialysate in peritoneal dialysis.Perit Dial Int1991; 11: 179–80.
3.
Passlick-DeetjenJ.The importance of biocompatibility in peritoneal dialysis solutions.Perit Dial Int1993; 13(Suppl 2): 101–4.
4.
PedersenF.B.Biocompatibility studies with bicarbonate-based solutions. In: KhannaR., ed. Advances in peritoneal dialysis, Toronto: Peritoneal Dialysis Publications, 1994; 10: 245–50.
5.
TopleyN., AlobaidiH.M.M., DaviesM.The effect of dialysate on peritoneal phagocyte oxidative metabolism.Kidney Int1988; 34: 404–11.
6.
KristensenS.R., PedersenF.B.Cytotoxicity testing of two CAPD dialysis fluids in a model system of quiescent fibroblastsNephrol Dial Transplant1993; 8: 163–7.
7.
RajpootD., ZhangJ., KaupkeC.J.Effect of conventional acidic glucose-based peritoneal dialysates (GPDS) on leucocyte adhesion receptor expression (Abstract).J Am Soc Nephrol1994; 5: 471.
8.
AlobaidiH.M., ColesG.A., DaviesM., LloydD.Host defence in continuous ambulatory peritoneal dialysis: the effect of the dialysate on phagocyte functionNephrol Dial Transplant1986; 1: 16–21.
9.
LiberekT., TopleyN., JörresA.Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH.Nephron1993; 65: 260–5.
10.
SchambyeH.T., PedersenF.B., WangP.Cytotoxicity of continuous ambulatory peritoneal dialysis (CAPD) solutions. A biocompatibility study involving human polymorphonuclear granulocytes rather than laboratory animals.ATLA1992; 20: 275–9.
11.
JörresA., TopleyN., WitowskiJ.Impact of peritoneal dialysis solutions on peritoneal immune defense.Perit Dial Int1993; 13(Suppl 2): 291–4.
12.
JörresA., JörresD., GahlG.M.Leukotriene B4 and tumor necrosis factor release from leukocytes: effect of peritoneal dialysate.Nephron1991; 58: 276–82.
13.
Di PaoloN., GarosiG., TraversariL.Mesothelial biocompatibility of peritoneal dialysis solutions.Perit Dial Int1993; 13(Suppl 2): Sl09–12.
14.
SchambyeH.T., PedersenF.P., WangR.Bicarbonate is not the ultimate answer to the biocompatibility problems of CAPD solutions: a cytotoxicity test of CAPD solutions and effluents. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin, 1992; 8: 42–6.
15.
DeFijterC.W.H., VerbrughH.A., PetersE.D.J.Invivo exposure to the currently available peritoneal dialysis fluids decreases the functions of peritonealmacrophages in CAPD.Clin Nephrol1993; 39: 75–80.
16.
SteinhauerH.B., BruggerU., AtmanspacherR.Effect of CAPD dialysate on the release of eicosanoids and cytokines from human peritoneal macrophages. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin, 1992; 8: 47–52.
17.
BreborowiczA., PatrikareaA., MarlisL., OreopoulosD.G.Effect of the dialysate effluent from CAPD patients on peritoneal mesothelial cells and fibroblast. In: KhannaR., ed. Advances in peritoneal dialysis, Toronto: Peritoneal Dialysis Publications, 1994; 10: 230–4.
18.
FougerayS., SlingeneyerA., BastideJ.M.Dialysis solutions buffered with lactate or bicarbonate: in vitro comparison of two dialysis solutions on human peritoneal cell growth from ESRD and non-ESRD patients. In: KhannaR., ed. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Publications, 1994; 10: 238–40.
19.
DuweA.K., VasS.I., WeatherheadJ.W.Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro.Infect Immun1981; 33: 130–5.
20.
PedersenF.B., RyttovN., DeleuranP.Acetate versus lactate in peritoneal dialysis solutions.Nephron1985; 35: 55–8.
21.
ZhouX.J., YuA.W., ZhouF.Q.Effects of an acidic, lactate-based peritoneal dialysis solution and its euhydric, bicarbonate-based counterpart on neutrophilic intracellular pH.Int J Artif Organs1993; 16: 816–19.
22.
SimchowitzL., TextorJ.A.Lactic acid secretion by human neutrophils. Evidence for an H++ lactatecotransport system.J Gen Physiol1992; 100: 341–67.
23.
BorregaardN.The respiratory burst of phagocytosis: biochemistry and subcellular localization.Immunol Lett1985; 11: 165–71.
24.
BorregaardN., HerlinT.Energy metabolism of human neutrophils during phagocytosis.J Clin Invest1982; 70: 550–7.
25.
SimchowitzL.Intracellular pH modulates the generation of superoxide radicals by human neutrophils.J Clin Invest1985; 76: 1079–89.
26.
DixonS.R., McKeanW.I., PryorJ.E., IrvineR.O.H.Changes in acid-base balance during peritoneal dialysis with fluid containing lactate ions.Clin Sci1970; 39: 51–60.
27.
VeechR.L.The toxic impact of parenteral solutions on the metabolism of cells: a hypothesis for physiological parenteral therapy.Am J Clin Nutr1986; 44: 519–51.
28.
BrunkhorstR., MahioutA.Pyruvate as non-toxic peritoneal dialysate (PD) buffer: maintained mesothelial cell (MC) integrity and proliferation (Abstract).J Am Soc Nephrol1994; 5: 410.
29.
MahioutA., BrunkhorstR.Development of a new CAPD solution using the anion pyruvate as buffer improving peritoneal host defence (Abstract).J Am Soc Nephrol1994; 5: 421.
30.
YamamotoT., SakakuraT., YamakawaM.Clinical effects of long-term use of neutralized dialysate for continuous ambulatory peritoneal dialysis.Nephron1992; 60: 324–9.
31.
JörresA., GahlG.M., TopleyN.In-vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions.Nephrol Dial Transplant1994; 9: 785–90.
32.
FerianiM., DissegnaD., La GrecaG., Passlick-DeetjenJ.Continuous ambulatory peritoneal dialysis with bicarbonate buffer a pilot study.Perit Dial Int1993; 13(Suppl 2): 88–91.
33.
FerianiM., Passlick-DeetjenJ., BrownC.An open controlled randomized clinical trial with bicarbonate CAPD solutions: interim results (Abstract).J Am Soc Nephrol1994; 5: 414.
